Trial Design
Clinical Trial Phases
Clinical trial phases are the sequential stages of human drug testing; Phase 1 evaluates safety in small healthy or patient cohorts, Phase 2 tests efficacy and dose in target patients, Phase 3 confirms efficacy and safety at scale to support marketing approval, and Phase 4 monitors long-term outcomes after approval.
Phase 1 trials enroll 20; 100 participants and focus on pharmacokinetics, pharmacodynamics, maximum tolerated dose, and basic safety. Phase 2 enrolls roughly 100; 300 patients with the target condition and seeks proof-of-concept efficacy plus dose-finding. Phase 3 enrolls hundreds to thousands of patients across many sites and is the primary basis for FDA, EMA, and PMDA approval decisions. Phase 4 (post-marketing surveillance) studies real-world safety, rare adverse events, and additional indications after approval.
Adaptive and seamless designs increasingly blur these boundaries, with Phase 1/2 oncology trials and Phase 2/3 platform trials running combined protocols under a single IND to compress timelines.
Related terms
Phase 1, 2, 3, and 4 Clinical Trials
Clinical trials are conducted in four sequential phases: Phase 1 evaluates safety and pharmacokinetics in a small cohort; Phase 2 evaluates efficacy and dose; Phase 3 confirms efficacy and safety in large randomized populations to support marketing approval; Phase 4 monitors real-world safety and effectiveness post-approval.
IND Application (Investigational New Drug)
An Investigational New Drug (IND) application is the submission a sponsor files with the FDA to obtain authorization to ship an unapproved drug across state lines and to administer it to humans in a clinical trial.
Endpoint (Clinical Trial)
A clinical trial endpoint is a defined, measurable outcome that determines whether the intervention being studied has the intended effect; it is the variable on which the trial's success or failure is statistically evaluated.
Adaptive Trial Design
An adaptive trial design is a clinical trial that uses pre-specified rules to modify aspects of the study (sample size, randomization ratio, dose, treatment arms, endpoints) based on accumulating interim data, without compromising scientific validity.
See how Kitsa applies this in your trials
Kitsa's agentic AI compresses protocol development, site selection, and patient pre-screening from months into weeks.
Request a demo